- Home
- FURY vs TTRX Comparison
FURY vs TTRX Comparison
Compare FURY & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FURY | TTRX |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 116.0M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | FURY | TTRX |
|---|---|---|
| Price | $0.59 | $3.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $1.70 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 473.4K | 20.8K |
| Earning Date | 05-13-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $2.57 |
| 52 Week High | $1.02 | $5.98 |
Technical Indicators
Market Signals| Indicator | FURY | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.45 | 51.33 |
| Support Level | $0.49 | $2.98 |
| Resistance Level | $0.63 | $3.73 |
| Average True Range (ATR) | 0.04 | 0.24 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 59.65 | 77.40 |
Price Performance
Historical ComparisonAbout FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About TTRX Turn Therapeutics Inc.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.